mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.
about
Pulmonary capillary hemangiomatosis: a focus on the EIF2AK4 mutation in onset and pathogenesisCrosstalk between cancer cells and blood endothelial and lymphatic endothelial cells in tumour and organ microenvironmentThe cancer theory of pulmonary arterial hypertension.Overnutrition, mTOR signaling, and cardiovascular diseases.Human umbilical cord blood mononuclear cells in a double-hit model of bronchopulmonary dysplasia in neonatal mice.The flavonoid quercetin reverses pulmonary hypertension in rats.A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension.Profiling the role of mammalian target of rapamycin in the vascular smooth muscle metabolome in pulmonary arterial hypertension.Senescent Cells Contribute to the Physiological Remodeling of Aged LungsAgonistic Anti-PDGF Receptor Autoantibodies from Patients with Systemic Sclerosis Impact Human Pulmonary Artery Smooth Muscle Cells Function In Vitro.Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.HIF and pulmonary vascular responses to hypoxia.Emerging role of selective autophagy in human diseases.Autophagy in lung disease pathogenesis and therapeutics.Allosteric therapies for lung cancer.Chronic thromboembolic pulmonary arterial hypertension: a review of the literature and novel therapeutic approaches.Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.Lung Circulation.Phase II study evaluating efficacy and safety of everolimus with letrozole for management of advanced (unresectable or metastatic) non-small cell lung cancer after failure of platinum-based treatment: a preliminary analysis of toxicity.Mechanisms underlying a decrease in KCl-induced contraction after long-term serum-free organ culture of rat isolated mesenteric artery.Reactive Oxygen Species in COPD-Related Vascular Remodeling.cPKCγ-mediated down-regulation of UCHL1 alleviates ischaemic neuronal injuries by decreasing autophagy via ERK-mTOR pathway.Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats.A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension.Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model.
P2860
Q26795562-CDAC9DC2-8E77-498F-822E-69DD9F7C4DEEQ28081431-975BEB16-48D7-4DDA-BB07-54D9F7D0FB28Q33788493-D22A12A8-994F-4944-BFD1-43C15BAFB2F9Q34519316-E07B1D87-BA7D-4BC5-8239-C047DFC8EC94Q34999298-5D56E028-EFD8-4EBC-9E4F-F1B2F8F6511CQ35474605-42C910FC-3FFE-49BB-B8AB-1850BA12AD8AQ35676912-9B9606D4-7CDF-4AAA-B46D-C7726EF18BE1Q36352098-EAFBA52C-9548-4F16-BE35-4AC1AC20C1DEQ36885316-03D3D115-8783-430E-8E88-B20C24DDAA39Q37629847-4BE75FEA-625F-4253-8709-E9C056B4996EQ37670612-7ECFA03C-839E-433E-848F-74ED103D6290Q37679350-16B11ED4-C4F4-4C43-941A-F7029F334902Q38270177-E744F11E-0BAB-46F1-A6E3-746BA29F56A3Q38330890-4A24950A-D344-4F23-B371-2EC1DD00977BQ38465098-7E7A83EC-48F6-41CE-9591-BDF6934797D2Q38479613-8055A10B-84AF-4037-90A8-DD8934CCBF7CQ38692684-01C825D2-1E88-4515-A4A8-02B8D9659054Q38804579-3170F8E4-A58B-4CFB-BC32-F4CAE7C9A776Q41696683-14A063FD-D2CE-4C37-9E54-25A42DBE5A82Q42127988-BCD51295-77D8-4242-84D8-6190643E3CE0Q46280803-A7BC3DAD-AA8B-48BF-8DAB-140B11E9DC9BQ47130601-B10B38AF-8F01-457D-935F-E3FD2529B8FBQ47966441-6C8EC23E-6CCD-4881-B7E3-2D36DDC6107FQ48150398-54D76676-6481-408A-8CEC-A969CB022A0DQ51018362-494028AE-CD06-42B8-8394-6F64B73E551E
P2860
mTOR and vascular remodeling in lung diseases: current challenges and therapeutic prospects.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
mTOR and vascular remodeling i ...... ges and therapeutic prospects.
@en
type
label
mTOR and vascular remodeling i ...... ges and therapeutic prospects.
@en
prefLabel
mTOR and vascular remodeling i ...... ges and therapeutic prospects.
@en
P2860
P356
P1433
P1476
mTOR and vascular remodeling i ...... ges and therapeutic prospects.
@en
P2093
Elena A Goncharova
P2860
P304
P356
10.1096/FJ.12-222224
P407
P577
2013-01-25T00:00:00Z